Safety of Lung Resection Surgery in Patients with History of SARS-CoV-2 Infection in the Post-vaccination Era: A Single Center Experience

P0145 

Abstract Submission 

Somin Im (1), Kwon Joong Na (1), Ji Hyeon Park (1), Bubse Na (1), Samina Park (1), In Kyu Park (1), Chang Hyun Kang (1), Young Tae Kim (1)

(1) Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, South Korea

Somin Im    -  Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital

Kwon Joong Na    -  Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital

Jihyeon Park    -  Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital

Bubse Na    -  Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital

Samina Park    -  Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital

*In Kyu Park    -  Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital

Chang Hyun Kang    -  Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital

*Young Tae Kim    -  Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital

Somin Im    -  Contact Me
N/A

Objective: SARS-CoV-2 pandemic poses an unanticipated challenge in lung resection surgery. Although the number of infection cases has increased, there have been more cases of mild illness recently since the SARS-CoV-2 vaccine has shown great efficacy and effectiveness in real-world data. The purpose of this study was to investigate the postoperative outcomes of lung resection surgery in patients with SARS-CoV-2 infection in order to discover the optimal timing of lung surgery following SARS-CoV-2 in the post-vaccination era.
Methods: This study is a retrospective single-center study, which included patients who underwent lung resection surgery from June 2021 to June 2022. The patients were divided into two groups based on their SARS-CoV-2 infection status before to surgery, and their postoperative outcomes were compared.
Results: A total of 1,197 patients underwent lung resection surgery during this period, of which 79 patients had a history of SARS-CoV-2 infection before surgery. In SARS-CoV-2 group, sixty-six patients (90.4%) received at least one dose of vaccination, and the most common symptoms were cough (52.0%), sore throat (44.0%), and sputum (41.3%). Eight patients had preoperative CT scans that suggested SARS-CoV-2 sequelae, yet surgery was nonetheless performed on them as they had no respiratory symptoms. There was no patient whose surgery was canceled due to SARS-CoV-2 infection. Minimally invasive surgery was performed in 74 patients (93.7%). The types of operation performed included wedge resection (N = 20, 25.3%), segmentectomy (N = 8; 10.1%), lobectomy (N = 47; 59.5%), bilobectomy (N = 3; 3.8%), and pneumonectomy (N = 1; 1.3%). The interval between SARS-CoV-2 infection to surgery was < 4weeks (18 patients), 4-6 weeks (18 patients), 6-8 weeks (11 patients), and > 8 weeks (32 patients). The complication rate (27.8% vs. 44.4% vs. 0 vs. 18.8%) and length of stay (average 5.3 vs. 5.3 vs. 3.1 vs. 5.2 days) were not different according to the interval between infection and surgery. When we compared postoperative outcomes between SARS-CoV-2 group and non-SARS-CoV-2 group, there was no statistical difference regarding major complication rate (6.3 % vs. 6.2%; p = 1.000), respiratory complication rate (19.0% vs. 12.9%; p = 0.122), and length of stays (4.9±3.4 vs. 5.0±6.0; p = 0.955).
Conclusions: In the post-vaccination era, lung resection surgery can be safely performed after SARS-CoV-2 infection, even in a short period of less than 6 weeks after

Lung Cancer